Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from AbbVie, Inc.

Presented through a collaboration between United States and Canadian Academy of Pathology and Physicians’ Education Resource®, LLC.


How to Leverage Pathologic Assessments to Guide Evidence-Based AML Care Planning

Release Date: July 30, 2021
Expiration Date: July 30, 2022

Activity Overview

This educational activity is a case-based virtual satellite webcast presented in association with the 2021 United States and Canadian Academy of Pathology (USCAP) annual meeting. The content focuses on optimizing pathologic assessment and management of patients with acute myeloid leukemia (AML) and includes a discussion of the latest diagnostic guidelines in AML, current targeted treatments, and optimal application of novel diagnostic and therapeutic strategies. A multidisciplinary panel of oncology pathologists and medical oncologists consider evolving pathologic testing methodologies, including the role of measurable residual disease (MRD) in diagnosis and treatment guidance and implementation of a collaborative approach to relevant and challenging clinical cases.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AbbVie, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward pathologists and medical oncologists who treat patients with AML. Nurses, nurse practitioners, physician assistants and other healthcare professions (HCPs) involved in the treatment and management of hematologic malignancies, specifically AML, will also be invited to participate in the activity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Outline current guideline-based recommendations for pathologic testing in AML including recent updates to CAP-ASH guidelines.
  • Assess the roles for multidisciplinary team members to incorporate prognostic and predictive biomarker testing along the disease continuum in AML.
  • Evaluate recently reported safety and efficacy for evolving treatment options among patients with AML.
  • Explain AML testing methodologies and how these may be applied to facilitate diagnosis and monitoring of patients with these hematologic malignancies.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Daniel A. Arber, MD
Daniel A. Arber, MD
Donald West and Mary Elizabeth King Professor and Chair
Department of Pathology
University of Chicago
Chicago, IL

Disclosures: Daniel A. Arber, MD, has no relevant financial relationships with ineligible companies.


Courtney D. DiNardo, MD, MSCE
Courtney D. DiNardo, MD, MSCE
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AbbVie, Agios Pharmaceuticals, Celgene Pharmaceutical, Daiichi Sankyo, ImmuneOne; Consultant: AbbVie, Agios, Celgene Pharmaceutical, Gilead Sciences, ImmuneOne, Novartis Pharmaceutical, Takeda Pharmaceuticals; Stock/Shareholder: Notable Labs.

Joseph D. Khoury, MD, FCAP, CMQ
Joseph D. Khoury, MD, FCAP, CMQ
Professor, Department of Hematopathology
Executive Director, MD Anderson Cancer Network
Division of Pathology and Laboratory Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Joseph D. Khoury, MD, has no relevant financial relationships with ineligible companies.

Jerald Radich, MD
Jerald Radich, MD
Professor, Clinical Research Division
Kurt Enslein Endowed Chair
Fred Hutchinson Cancer Research Center
Professor, Division of Medical Oncology
University of Washington School of Medicine
Seattle, WA

Disclosures: Consultant: Amgen, Genentech, BMS, Novartis Pharmaceutical.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By